Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Teladoc and LifeMD are partnering with drugmaker Eli Lilly to offer the weight loss drug Zepbound directly to self-paying patients. The two telehealth companies said Thursday they’re working ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 25 trades. If we consider the specifics of each ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

Eli Lilly LLY-0.69%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...